ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / SYRE
MDGL (38) PTGX (65) TGTX (63) BMRN (74) ⌘ Pro Terminal →

Spyre Therapeutics Inc. (SYRE) — RQD Stock Rating Cockpit

$96.56 -2.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $95.96

Spyre Therapeutics Inc. (SYRE) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY) →
ROARABLE D+ • SELL / AVOID Cap $10.08B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SYRE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Spyre Therapeutics Inc. (NASDAQ: SYRE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $96.56 (-2.42% 1D, market cap $10.08B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, SYRE ranks #203 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SYRE compare to MDGL and PTGX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SYRE carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.0%. By comparison, MDGL (Madrigal Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B) and PTGX (Protagonist Therapeutics Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SYRE?
▼

Per SYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636282), Spyre Therapeutics Inc. generated $0 in revenue, -$155.2M in net income, and -$169.3M in free cash flow against $777.8M in total assets and $28.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $95.95 (-0.63%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510055
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+
Cash (5)Whales (17)SEC (16)Macro (11)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-1.3% Base Target
$116 Bull$95 Base$74 Bear
📬 FREE SYRE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SYRE)Realized 20D OHLCV Swing Band: ±9.6%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY SYRE SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (31% of score)

20D Institutional Volume Accumulation (±9.6% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (29% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)

Capital intensity & 0% operating margin leave 15 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
47
Grade D$78.63+18.2% Next Q
Q2 (-2Q)
50
Grade C-$92.95+7.3% Next Q
Q3 (-1Q)
52
Grade C-$99.75-3.2% Next Q
Current
55
Grade D+$96.56-0.5% Hist 90D α
Trajectory: D (47) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SYRE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, SYRE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($89.54) or 200D SMA ($74.19) invalidates the momentum regime and cuts Target Base ($95.26) toward Bear Floor ($74.30).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SYRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SYRE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 55%NO 45%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
57.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
26.00>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE85% OF RANGE
L: $21$96.56H: $110
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on SYRE

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-20.0% ROIC with 42.0% gross margin and -1.64% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 26.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (57)

23/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like SYRE
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SYRE)

  • ✓Walkthrough of SYRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SYRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +39.68%⚡ TESTING RESISTANCE
2026-11-03O $98.96H $98.96L $96.56C $96.56VOL 661.2K
RES: $99.64SUP: $78.53SMA50: $89.54SMA200: $74.19
$115.7$92.87$70.05$47.23$24.41RES $99.64SUP $78.53$96.562026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SYRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SYRE Butterfly Map → + Track SYRE →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
15.7%/yr Implied 5Y Growth

vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SYRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SYRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SYRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SYRE)

Health Care Rank #203 of 1016 ⚔️ MDGL vs SYRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SYRE vs. MDGL, PTGX, TGTX, BMRN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Spyre Therapeutics Inc. (SYRE) ranks #203 by composite RQD confidence (55/100, grade D+) and #109 by equity capitalization ($10.08B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with SYRE at 55/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SYRE ACTIVE
Spyre Therapeutics Inc.
D+ 55/100 — — -20.0% -2.42% $10.08B Benchmark Subject
MDGL
Madrigal Pharmaceuticals Inc.
D- 38/100 — — -29.7% -0.31% $9.94B /mdgl-vs-syre →
PTGX
Protagonist Therapeutics Inc.
C 65/100 — — -16.7% +0.35% $9.37B /ptgx-vs-syre →
TGTX
TG Therapeutics Inc.
C 63/100 19.9x 83.7% 12.0% +5.34% $9.36B /tgtx-vs-syre →
BMRN
BioMarin Pharmaceutical Inc.
B 74/100 31.9x 77.7% 6.0% +1.77% $11.33B /bmrn-vs-syre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001636282

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Spyre Therapeutics Inc. (SYRE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$155.2M, operating cash flow of -$169.3M, and free cash flow of -$169.3M (-7.5% YoY). On the balance sheet, SYRE closed FY2025 with $777.8M in total assets against $28.1M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$155.2M -$169.3M -$169.3M $777.8M $28.1M
FY2024 (FY) 2024-12-31 $0 -$208.0M -$157.4M -$157.4M $608.5M $40.8M
FY2023 (FY) 2023-12-31 $886.0K -$338.8M -$99.9M -$99.9M $5.68B $1.33B

3. SYRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Spyre Therapeutics Inc. (NASDAQ: SYRE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $96.56 (-2.42% 1D, market cap $10.08B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, SYRE ranks #203 in composite RQD confidence.

How does SYRE compare to MDGL and PTGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SYRE carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.0%. By comparison, MDGL (Madrigal Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B) and PTGX (Protagonist Therapeutics Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SYRE?

Per SYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636282), Spyre Therapeutics Inc. generated $0 in revenue, -$155.2M in net income, and -$169.3M in free cash flow against $777.8M in total assets and $28.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SYRE trading relative to its 50-day, 200-day, and 52-week technical levels?

SYRE last traded at $96.56 (-2.42% on volume of 661,175 shares), positioning the stock +7.84% above its 50-day simple moving average ($89.54) and +30.15% above its 200-day simple moving average ($74.19). Across its 52-week range of $21.15 to $110.18, SYRE sits at the 84.7% percentile with a 14-day RSI of 57.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.6% ($87.29 to $105.83).

SYRE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SYRE stock right now?

Spyre Therapeutics Inc. (SYRE) currently earns a Roarable Rating of D+ (Sell — SELL) with 55/100 RQD Confidence. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.

What is SYRE's 12-month price target and RQD AI Jury consensus?

SYRE's 12-month base price target is $95.26 (range $74.3 to $115.69), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SYRE RQD Cockpit SYRE 12M Forecast SYRE Earnings & Move SYRE Dividends & DRIP SYRE Insiders & 13F SYRE Whale Options SYRE Profit Sankey SYRE News & Why
ROARABLE RATING BRIEF • RQD 55/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SYRE — Spyre Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:26Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SYRE holds an RQD Score of 55, letter grade D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

  • Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, ROIC is -20% and FCF yield is -1.64%. This is the weakest pillar and the main reason the overall score is low. For a prospective investor, the company is not currently generating returns on invested capital or positive free cash flow, so value depends on future outcomes not yet visible in reported results.
  • Whale 13F Flow: 17 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar and signals that large holders are positioned constructively, though the source does not itemize holders (see Analyst View section).
  • Insider Conviction: 6 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider conviction signals in the source data.
  • Macro Regime Fit: 11 / 20. Per the Roarable RQD rating, beta is 0.89 with sector sensitivity noted. The stock's sensitivity to broad market moves is below 1.0, but the score is mid-range, indicating the regime fit is neither strongly supportive nor strongly adverse.
  • Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, Altman Z is 26, Piotroski F is 5/9, and Debt/Equity is 0.04. Leverage is minimal and solvency metrics are strong, which partially offsets the weak cash engine.

Investor implications: the upside case rests on institutional positioning and a clean balance sheet giving runway, while valuation tradeoffs are significant given negative EPS (-1.49 TTM) and a forward P/E of 22 against a market cap of $10.33B. The rating's "Trim" verdict reflects that fundamentals currently do not support the price on cash-flow metrics.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-209.6M$-155.2MN/A$-169.3M$85.7M$28.1M
FY 2024$0.0M$-208.6M$-208.0MN/A$-157.4M$89.4M$40.8M
FY 2023$0.9M$-242.3M$-338.8MN/A$-99.9MN/A$1329.8M

Per the SEC financials, the company reported operating losses across all three periods, with gross, operating, and net margins each shown as 0% in the market data. Per the market data, ROIC is -20%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 5/9. Per the SEC financials, debt fell from $1329.8M (FY 2023) to $28.1M (FY 2025), and Debt/Equity is 0.04 per the RQD forensic pillar.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most prominent item is a RED-light "RISK WATCH" headline reporting that the stock fell on a public offering launch, with a companion marketscreener headline announcing a proposed public offering of common stock. Additional YELLOW-light "MARKET WIRE" items cover a sliding share price, a possible fully-priced valuation following IBD data, estimates coverage, and a Seeking Alpha note referencing "SPY072" shots on goal in Q4 2026 and IBD combination potential. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links or proprietary signals.

Open Questions

  • What are the terms, size, and proceeds of the proposed public offering, and how would it affect share count and dilution?
  • What products or clinical programs drive the company, and what is their development timeline?
  • What explains the gap between the negative EPS (-1.49 TTM) and the forward P/E of 22?
  • What is the FY 2025 cash runway given $85.7M cash against $-169.3M free cash flow?
  • What do the "SPY072" and IBD combination references in the news feed represent, and what are their timing and risk profiles?

SYRE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Spyre Therapeutics Inc. (SYRE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SYRE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SYRE Bull vs. Bear Conversation Board — What's Your Call at $96.56?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SYRE 🐻 50% BEARISH CONVICTION
1. Pick Your Side on SYRE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $106.88 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SYRE (D+ • RQD 55/100) a Buy at $98.96?

Welcome to the SYRE (Spyre Therapeutics Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $78.18 (-21.0%)
Spot @ $98.96

Pump the brakes on SYRE — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SYRE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Spyre Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $122.71 (+24.0%)
Spot @ $98.96

SYRE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SYRE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $98.96 (52-wk range $21.15 - $110.18), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%